Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/819
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Hydrocortisone Valerate (Cream)
|
| dailymed-instance:dosage |
Hydrocortisone valerate cream USP, 0.2% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Hydrocortisone valerate cream USP, 0.2% should not be used with occlusive dressings unless directed by a physician. Hydrocortisone valerate cream USP, 0.2% should not be applied in the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing.
|
| dailymed-instance:descripti... |
Hydrocortisone valerate cream USP, 0.2% contains hydrocortisone valerate, 11,21-dihydroxy-17-[(1-oxopentyl)oxy]-(11��)-pregn-4-ene-3,20-dione, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, hydrocortisone valerate is CHO. It has the following structural formula: Hydrocortisone valerate has a molecular weight of 446.58. It is a white, crystalline solid, soluble in ethanol and methanol, sparingly soluble in propylene glycol and insoluble in water. Each gram of hydrocortisone valerate cream USP, 0.2% contains 2mg hydrocortisone valerate in a hydrophilic base composed of white petrolatum, stearyl alcohol, propylene glycol, amphoteric-9, carbomer 940, dibasic sodium phosphate, sodium lauryl sulfate, sorbic acid and water.
|
| dailymed-instance:clinicalP... |
Like other topical corticosteroids, hydrocortisone valerate has anti-inflammatory, antipruritic and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase Ainhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A.<br/>Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Studies performed with hydrocortisone valerate cream USP, 0.2% indicate that it is in the medium range of potency as compared with other topical corticosteroids.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Hydrocortisone valerate cream USP, 0.2% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
|
| dailymed-instance:supply |
Hydrocortisone valerate cream USP, 0.2% is supplied in the following tube sizes: 15 g, 45g and 60g Store below 78��F (26��C).
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... |
dailymed-ingredient:amphoteric-9,
dailymed-ingredient:carbomer_940,
dailymed-ingredient:dibasic_sodium_phosphate,
dailymed-ingredient:propylene_glycol,
dailymed-ingredient:sodium_lauryl_sulfate,
dailymed-ingredient:sorbic_acid,
dailymed-ingredient:stearyl_alcohol,
dailymed-ingredient:water,
dailymed-ingredient:white_petrolatum
|
| dailymed-instance:overdosag... |
Topically applied hydrocortisone valerate cream USP, 0.2% can be absorbed in sufficient amounts to produce systemic effects .
|
| dailymed-instance:genericMe... |
Hydrocortisone Valerate
|
| dailymed-instance:fullName |
Hydrocortisone Valerate (Cream)
|
| dailymed-instance:adverseRe... |
The following local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. In controlled clinical studies involving pediatric patients one month to 2 years of age (n=29), the incidence of adverse experiences, regardless of relationship to the use of hydrocortisone valerate cream USP, 0.2% was approximately 21%. Reported reactions included stinging (10%), eczema (7%), fungal infection (3%), and gastrointestinal disorder (3%). In controlled clinical studies involving pediatric patients 2 to 12 years of age (n=153), the incidence of adverse experiences, regardless of relationship to the use of hydrocortisone valerate cream USP, 0.2% was approximately 10%. Reported reactions included stinging (3%), burning skin (2%), infection (Body as a Whole) (2%). Skin irritation, eczema, pruritus, application site reaction, rash, rash maculopapular, and dry skin were all reported at incidences of approximately 1%.
|
| dailymed-instance:indicatio... |
Hydrocortisone valerate cream USP, 0.2% is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Hydrocortisone Valerate
|